# Anti-dipeptidyl-peptidase-like protein-6 (DPPX) autoimmune encephalitis associated with severe multifocal dystonia

## TL;DR

This paper reports a rare case of anti-DPPX encephalitis presenting with severe dystonia, a symptom not previously associated with this condition.

## Contribution

The study identifies dystonia as a novel clinical manifestation of anti-DPPX encephalitis.

## Key findings

- Dystonia can be a presenting feature of anti-DPPX encephalitis.
- Immunosuppressive therapy is effective in treating anti-DPPX encephalitis.
- Botulinum toxin may help alleviate dystonia symptoms in this condition.

## Abstract

•Anti-DPPX encephalitis is characterized by complex symptoms, including movement disorder.•Dystonia has not been described as a phenomenon of anti-DPPX encephalitis.•Immunosuppressive therapy is the mainstay of treatment for anti-DPPX encephalitis.•Botulinum toxin administration may improve the symptoms of dystonia in anti-DPPX encephalitis.

Anti-DPPX encephalitis is characterized by complex symptoms, including movement disorder.

Dystonia has not been described as a phenomenon of anti-DPPX encephalitis.

Immunosuppressive therapy is the mainstay of treatment for anti-DPPX encephalitis.

Botulinum toxin administration may improve the symptoms of dystonia in anti-DPPX encephalitis.

Anti-DPPX encephalitis is a rare form of autoimmune encephalitis characterized antibodies against a subunit of Kv4.2 potassium channels. Characteristic clinical features include cognitive dysfunction, parasomnias, psychosis, and seizures. Motor symptoms typically include myoclonus, tremor, and midline ataxia. DPPX encephalitis presenting as new-onset focal dystonia has not been previously described.